Ge Long Hui·2026-01-27 10:15Core Viewpoint - The announcement highlights that HRS-5346, a drug developed by the subsidiary of the company, has been included in the list of breakthrough therapies by the National Medical Products Administration, indicating significant progress in addressing elevated lipoprotein(a) levels, a common genetic lipid disorder linked to cardiovascular diseases [1]. Group 1: Drug Development - HRS-5346 is an oral small molecule inhibitor targeting lipoprotein(a) [Lp(a)], which is a significant independent risk factor for atherosclerotic cardiovascular diseases [2]. - The drug is notable as there are currently no similar products approved for market in both domestic and international contexts [1]. - The total research and development investment for HRS-5346 has reached approximately 76.3 million yuan (un-audited) [1]. Group 2: Market Context - Elevated Lp(a) levels are prevalent, with a reported prevalence of 18.67% for levels above 30 mg/dL and 8.41% for levels above 50 mg/dL among Chinese adults [1]. - Targeting Lp(a) through lipid-lowering therapies represents a crucial breakthrough direction in the prevention and treatment of cardiovascular diseases [2].